Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generic Pomalidomide + Low-Dose Dex in RRMM
NCT05236621Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Jun 2022
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pomalidomide in multiple myeloma (MM), sponsored by Qilu Pharmaceutical. Primary endpoint: Total Response Rate up to 104 weeks. Status: unknown.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05236621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05236621.